What does it take to build a successful biotech in the UK today? In September 2026, Blue Matter brought together 18 senior biopharma leaders in London for a candid discussion on commercialization strategy, financing and valuation, people and talent, and program development. This synthesis captures their perspectives on why commercial credibility is critical from day one, why focus beats breadth, and how UK companies can navigate selective capital markets and global routes to value. Download the full paper for the key takeaways and the UK market and policy context behind them.
